| Mechanistic determinants of biotherapeutics absorption following SC administration WF Richter, SG Bhansali, ME Morris The AAPS journal 14, 559-570, 2012 | 331 | 2012 |
| A phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors B Geoerger, F Bourdeaut, SG DuBois, M Fischer, JI Geller, NG Gottardo, ... Clinical Cancer Research 23 (10), 2433-2441, 2017 | 161 | 2017 |
| A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. JA Sosman, M Kittaneh, MPJK Lolkema, MA Postow, G Schwartz, ... Journal of Clinical Oncology 32 (15_suppl), 9009-9009, 2014 | 132 | 2014 |
| Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study M Gattorno, L Obici, M Cattalini, V Tormey, K Abrams, N Davis, A Speziale, ... Annals of the rheumatic diseases 76 (1), 173-178, 2017 | 112 | 2017 |
| PEG-conjugated highly dispersive multifunctional magnetic multi-walled carbon nanotubes for cellular imaging JJ Khandare, A Jalota-Badhwar, SD Satavalekar, SG Bhansali, ND Aher, ... Nanoscale 4 (3), 837-844, 2012 | 84 | 2012 |
| A comparative study of the effect of oxidative stress on the cytoskeleton in human cortical neurons PK Allani, T Sum, SG Bhansali, SK Mukherjee, M Sonee Toxicology and applied pharmacology 196 (1), 29-36, 2004 | 73 | 2004 |
| Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence F Wu, SG Bhansali, WC Law, EJ Bergey, PN Prasad, ME Morris Pharmaceutical research 29, 1843-1853, 2012 | 71 | 2012 |
| Abstract P3-14-01: phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2–breast cancer: safety, preliminary efficacy and molecular analysis D Juric, R Ismail-Khan, M Campone, L García-Estévez, C Becerra, ... Cancer Research 76 (4_Supplement), P3-14-01-P3-14-01, 2016 | 46 | 2016 |
| Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC). PN Munster, EP Hamilton, C Franklin, S Bhansali, K Wan, B Hewes, ... Journal of Clinical Oncology 32 (15_suppl), 533-533, 2014 | 36 | 2014 |
| Transferrin-mediated rapid targeting, isolation, and detection of circulating tumor cells by multifunctional magneto-dendritic nanosystem. SS Banerjee, A Jalota-Badhwar, SD Satavalekar, SG Bhansali, ND Aher, ... Advanced Healthcare Materials 2 (6), 800-805, 2012 | 32 | 2012 |
| Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections SG Bhansali, K Mullane, LSL Ting, JA Leeds, K Dabovic, J Praestgaard, ... Antimicrobial agents and chemotherapy 59 (3), 1441-1445, 2015 | 31 | 2015 |
| Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. A Bardia, S Modi, M Chavez-Mac Gregor, M Kittaneh, AJ Marino, ... Journal of Clinical Oncology 32 (15_suppl), 535-535, 2014 | 31 | 2014 |
| Nano-biomaterials for ophthalmic drug delivery Y Pathak, V Sutariya, AA Hirani Springer International Publishing, 2016 | 28 | 2016 |
| 3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma C Van Herpen, MA Postow, MS Carlino, H Kalkavan, A Weise, RN Amaria, ... European Journal of Cancer 3 (51), S663, 2015 | 26 | 2015 |
| Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2-breast cancer. PN Munster, EP Hamilton, LG Estevez, RH De Boer, IA Mayer, ... Journal of Clinical Oncology 32 (26_suppl), 143-143, 2014 | 26 | 2014 |
| Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2-breast cancer. PN Munster, EP Hamilton, LG Estevez, RH De Boer, IA Mayer, ... Journal of Clinical Oncology 32 (26_suppl), 143-143, 2014 | 26 | 2014 |
| Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2–advanced breast cancer A Bardia, S Modi, M Oliveira, M Campone, B Ma, L Dirix, A Weise, L Nardi, ... Cancer Research 76 (4_Supplement), P6-13-01-P6-13-01, 2016 | 25 | 2016 |
| Noninvasive real-time fluorescence imaging of the lymphatic uptake of BSA–IRDye 680 conjugate administered subcutaneously in mice F Wu, SG Bhansali, M Tamhane, R Kumar, LA Vathy, H Ding, KT Yong, ... Journal of pharmaceutical sciences 101 (5), 1744-1754, 2012 | 24 | 2012 |
| Abstract P5-19-24: phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2–breast cancer: safety, preliminary efficacy and molecular analysis D Juric, E Hamilton, L Garcia Estévez, RH De Boer, I Mayer, M Campone, ... Cancer Research 75 (9_Supplement), P5-19-24-P5-19-24, 2015 | 22 | 2015 |
| Phase Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF-mutant melanoma M Taylor, J Sosman, R Gonzalez, MS Carlino, M Kittaneh, MP Lolkema, ... Annals of Oncology 25, iv374, 2014 | 22 | 2014 |
Marilyn E. MorrisUniversity at BuffaloDirección de correo verificada de buffalo.edu
